Kisspeptin-10: Uses, Benefits & Research

What is Kisspeptin-10?

Kisspeptin-10 is the minimal active fragment of the kisspeptin family of peptide hormones encoded by the KISS1 gene. The full-length protein (kisspeptin-54) is a 54-amino acid peptide with a molecular weight of approximately 3,000 Da, while kisspeptin-10 represents the C-terminal decapeptide that retains full biological activity at the KISS1 receptor. Kisspeptin functions as the “master switch” for puberty and reproduction, serving as the upstream regulator of the entire hypothalamic-pituitary-gonadal (HPG) axis. It is currently investigational with no FDA approval, administered via subcutaneous injection with a half-life of approximately 30-60 minutes. A synthetic analog, MVT-602, demonstrates approximately 50-fold greater potency than the native peptide and is in active Phase 2 clinical development.

Mechanism of Action

Kisspeptin-10 binds to the KISS1 receptor (KISS1R/GPR54), a G-protein coupled receptor expressed primarily on GnRH neurons in the hypothalamus, as well as in pituitary gonadotrophs and peripheral tissues including the placenta, pancreas, ovaries, and testes.

Upon receptor binding, kisspeptin activates the Gq/11 signaling cascade, leading to phospholipase C (PLC) activation, IP3/DAG production, and intracellular calcium mobilization. This directly stimulates GnRH neurons to release gonadotropin-releasing hormone in a pulsatile fashion. GnRH then acts on the anterior pituitary to trigger release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which drive downstream sex hormone production and fertility. The MAPK/ERK pathway is also engaged, contributing to reproductive tissue effects.

The clinical significance of this mechanism is that kisspeptin provides targeted, physiological stimulation of the reproductive axis from the very top of the cascade, offering a more natural activation pattern compared to direct GnRH administration or downstream hormone supplementation.

Clinical Evidence

Human Studies

The kisspeptin evidence base includes 50+ human studies, primarily in reproductive endocrinology, with 10+ Phase 1-2 RCTs. No meta-analyses have been published yet given the early stage of development.

A Phase 2 trial (N=100) demonstrated that kisspeptin administration effectively increases oocyte yield in IVF settings. Notably, a single kisspeptin injection can stimulate an LH surge sufficient to trigger ovulation, positioning it as a potential alternative to hCG triggers in assisted reproduction. The compound has shown particular promise in patients with functional hypothalamic amenorrhea who have failed clomiphene — a population with limited treatment options.

MVT-602 completed a Phase 1 trial (N=40) establishing safety and favorable pharmacokinetics, and is currently in Phase 2 (NCT05896293, N=80) evaluating pregnancy rates. Additional Phase 2 trials (NCT06123451) are investigating ovulation rates, and Phase 1 safety/PK studies (NCT05418768) continue to enroll.

Male hypogonadism studies (N=50) have demonstrated increased testosterone production following kisspeptin administration, supporting its potential as a targeted treatment for hypothalamic hypogonadism in men.

Preclinical Research

Extensive preclinical work has established kisspeptin’s role as the critical upstream regulator of reproductive function. KISS1 and KISS1R knockout models demonstrate complete absence of pubertal development and fertility, confirming the essential nature of this signaling pathway. Animal studies have mapped the neuroanatomical distribution of kisspeptin neurons and elucidated the feedback loops connecting sex steroids to KISS1 gene expression.

Drug Interactions & Contraindications

Kisspeptin acts at the apex of the HPG axis, creating important interaction considerations:

• GnRH agonists/antagonists: Documented interaction — kisspeptin acts upstream of GnRH, and co-administration fundamentally alters HPG axis dynamics
• Hormonal contraceptives: May partially override the suppressive effects of exogenous hormones on the reproductive axis
• hCG: Potentially synergistic effects on ovulation; combination may be used intentionally in fertility protocols

Kisspeptin is contraindicated in hormone-sensitive cancers (breast, prostate, endometrial) due to its potent stimulation of reproductive hormones. It should not be used during pregnancy except under direct clinical supervision for fertility purposes. No formal drug interaction studies have been conducted.

Safety & Side Effects

Kisspeptin is generally well-tolerated with a manageable side effect profile based on Phase 1-2 trial data. The most common adverse event is injection site reaction (10-15%), followed by headache (5-10%), nausea (<5%), and flushing (<5%).

In the IVF context, ovarian hyperstimulation syndrome occurs in 2-5% of patients, consistent with any ovulation-inducing therapy. Multiple pregnancy risk is 1-2%, also in line with fertility treatment norms. No significant safety signals have been identified in trials to date, though long-term data beyond Phase 2 is limited.

Honest Bottom Line

Kisspeptin is a promising reproductive hormone in Phase 2 development for infertility in both men and women. As the upstream regulator of the HPG axis, it offers a novel mechanism for stimulating gonadotropin release — particularly valuable for patients with hypothalamic amenorrhea or suboptimal response to conventional fertility treatments. The evidence base includes 50+ human studies showing it can effectively trigger ovulation and improve fertility outcomes. However, kisspeptin remains investigational with no FDA approval as of March 2026. The main advantages are its targeted mechanism (direct KISS1R activation) and potential for fewer side effects compared to indirect stimulators. The main limitation is the lack of long-term safety data and FDA approval. Patients interested in kisspeptin therapy should seek clinical trial participation or discuss with reproductive endocrinology specialists.